StockData
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. (CADL) income statement

CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 1/30
$5.04−0.09 (-1.75%)

Close on Nov 20, 2026Market cap $385.65MP/E –Yield –

Candel Therapeutics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2025
-64.6%

Financial strength

Current ratio
16.09
Debt to equity
–
Debt to assets
–
Cash to current liabilities
1589.0%

Valuation

P/E ratio
–
Price to sales
–
Price to book
3.06
Dividend yield
–

See a number that looks wrong?